Physician profile
Mark Brinkman
NPI 1245764133
$6,569.48
in general payments reported to CMS, 2019-2025
41 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $591 · 2021: $1,290 · 2022: $789 · 2023: $1,372 · 2024: $1,501 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,790 · Gift: $59.40 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,790.49 |
| Gift | $59.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,017.60 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $600.67 | 2020-2024 | |
| Lilly USA, LLC | $596.83 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $518.12 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $476.86 | 2021-2025 | |
| Edwards Lifesciences Corporation | $459.69 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbvie INC. | $418.71 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.64 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $195.57 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $180.78 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Eisai INC. | $180.74 | 2020-2022 | |
| Mannkind Corporation | $155.85 | 2023-2024 | Afrezza |
| Astellas Pharma US INC | $134.76 | 2020-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $121.68 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.55 | 2022-2024 | Xifaxan |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brinkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.